

**NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE**

**TECHNOLOGY APPRAISAL PROGRAMME**

**Equality impact assessment – Scoping**

**STA Pembrolizumab for adjuvant treatment of melanoma with high risk of recurrence**

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

No issues were identified.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

N/A

3. Has any change to the draft scope been agreed to highlight potential equality issues?

N/A

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?

No additional stakeholders were identified.

**Approved by Associate Director:** Janet Robertson

Technology Appraisals: Scoping

Equality impact assessment for the Single Technology Appraisal of pembrolizumab for adjuvant treatment of resected melanoma with high risk of recurrence

Issue date: April 2017

1 of 2

**Date:** 27 March 2018